Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$44.79
-2.4%
$41.12
$33.02
$57.50
$16.18B1.852.66 million shs2.53 million shs
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
$59.28
-7.0%
$58.72
$47.09
$127.48
$51.21B1.8314.45 million shs48.27 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$23.46
+0.0%
$23.12
$20.92
$31.54
$133.55B0.5841.09 million shs56.58 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
0.00%+1.17%+14.38%-10.13%+7.33%
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
0.00%-2.32%-2.74%-35.44%-21.77%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+0.54%-1.87%-11.24%-15.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
4.8549 of 5 stars
3.24.02.52.63.52.52.5
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
4.9562 of 5 stars
4.45.00.83.03.03.31.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9832 of 5 stars
3.35.04.24.32.71.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
2.38
Hold$53.0018.33% Upside
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
2.83
Moderate Buy$94.2158.92% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1724.33% Upside

Current Analyst Ratings Breakdown

Latest MRVL, PFE, and CG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$100.00 ➝ $85.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$110.00 ➝ $90.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$70.00 ➝ $73.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$135.00 ➝ $133.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$110.00 ➝ $90.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$95.00 ➝ $85.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$115.00 ➝ $90.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$120.00 ➝ $95.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$60.00
5/30/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$100.00 ➝ $85.00
5/23/2025
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $49.00
(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$3.47B4.66$3.85 per share11.62$17.75 per share2.52
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
$5.77B8.88$1.33 per share44.57$17.16 per share3.45
Pfizer Inc. stock logo
PFE
Pfizer
$62.46B2.14$3.68 per share6.38$15.81 per share1.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$1.02B$2.9516.119.450.9818.81%24.02%6.53%8/4/2025 (Estimated)
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
-$933.40M-$1.02N/A29.641.61-27.49%4.59%3.20%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3816.647.740.6412.62%19.47%8.09%7/29/2025 (Estimated)

Latest MRVL, PFE, and CG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q1 2026
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
$0.61$0.62+$0.01$0.20$1.88 billion$1.90 billion
5/9/2025Q1 2025
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$0.97$1.14+$0.17$0.35$972.27 million$973.10 million
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
$1.403.13%+11.87%47.46%4 Years
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
$0.240.40%N/AN/A N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.33%+2.50%124.64%16 Years

Latest MRVL, PFE, and CG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
4/23/2025
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
quarterly$0.353.3%5/19/20255/19/20255/27/2025
3/20/2025
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
quarterly$0.060.34%4/11/20254/11/20255/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
1.42
2.32
2.32
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
0.30
1.60
1.11
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
55.88%
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
83.51%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
26.30%
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
0.33%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
The Carlyle Group Inc. stock logo
CG
The Carlyle Group
2,100361.14 million260.39 millionOptionable
Marvell Technology, Inc. stock logo
MRVL
Marvell Technology
6,730863.83 million862.45 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.69 billion5.66 billionOptionable

Recent News About These Companies

Terrible News for Pfizer Stock Investors
Pfizer Combo Halves Death Risk in BRAF V600E Cancer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
The Carlyle Group stock logo

The Carlyle Group NASDAQ:CG

$44.79 -1.09 (-2.38%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$45.22 +0.43 (+0.97%)
As of 05/30/2025 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Carlyle Group Inc. is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in management-led/ Leveraged buyouts, privatizations, divestitures, strategic minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid venture, late venture, PIPES. The firm invests across four segments which include Corporate Private Equity, Real Assets, Global Market Strategies, and Solutions. The firm typically invests in industrial, agribusiness, ecological sector, fintech, airports, parking, Plastics, Rubber, diversified natural resources, minerals, farming, aerospace, defense, automotive, consumer, retail, industrial, infrastructure, energy, power, healthcare, software, software enabled services, semiconductors, communications infrastructure, financial technology, utilities, gaming, systems and related supply chain, electronic systems, systems, oil and gas, processing facilities, power generation assets, technology, systems, real estate, financial services, transportation, business services, telecommunications, media, and logistics sectors. Within the industrial sector, the firm invests in manufacturing, building products, packaging, chemicals, metals and mining, forestry and paper products, and industrial consumables and services. In consumer and retail sectors, it invests in food and beverage, retail, restaurants, consumer products, domestic consumption, consumer services, personal care products, direct marketing, and education. Within aerospace, defense, business services, and government services sectors, it seeks to invest in defense electronics, manufacturing and services, government contracting and services, information technology, distribution companies. In telecommunication and media sectors, it invests in cable TV, directories, publishing, entertainment and content delivery services, wireless infrastructure/services, fixed line networks, satellite services, broadband and Internet, and infrastructure. Within real estate, the firm invests in office, hotel, industrial, retail, for sale residential, student housing, hospitality, multifamily residential, homebuilding and building products, and senior living sectors. The firm seeks to make investments in growing business including those with overleveraged balance sheets. The firm seeks to hold its investments for four to six years. In the healthcare sector, it invests in healthcare services, outsourcing services, companies running clinical trials for pharmaceutical companies, managed care, pharmaceuticals, pharmaceutical related services, healthcare IT, medical, products, and devices. It seeks to invest in companies based in Sub-Saharan focusing on Ghana, Kenya, Mozambique, Botswana, Nigeria, Uganda, West Africa, North Africa and South Africa focusing on Tanzania and Zambia; Asia focusing on Pakistan, India, South East Asia, Indonesia, Philippines, Vietnam, Korea, and Japan; Australia; New Zealand; Europe focusing on France, Italy, Denmark, United Kingdom, Germany, Austria, Belgium, Finland, Iceland, Ireland, Netherlands, Norway, Portugal, Spain, Benelux , Sweden, Switzerland, Hungary, Poland, and Russia; Middle East focusing on Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey, and UAE; North America focusing on United States which further invest in Southeastern United States, Texas, Boston, San Francisco Bay Area and Pacific Northwest; Asia Pacific; Soviet Union, Central-Eastern Europe, and Israel; Nordic region; and South America focusing on Mexico, Argentina, Brazil, Chile, and Peru. The firm seeks to invest in food, financial, and healthcare industries in Western China. In the real estate sector, the firm seeks to invest in various locations across Europe focusing on France and Central Europe, United States, Asia focusing on China, and Latin America. It typically invests between $1 million and $50 million for venture investments and between $50 million and $2 billion for buyouts in companies with enterprise value of between $31.57 million and $1000 million and sales value of $10 million and $500 million. It seeks to invest in companies with market capitalization greater than $50 million and EBITDA between $5 million to $25 million. It prefers to take a majority or a minority stake. While investing in Japan, it does not invest in companies with more than 1,000 employees and prefers companies' worth between $100 million and $150 million. The firm originates, structures, and acts as lead equity investor in the transactions. The Carlyle Group Inc. was founded in 1987 and is based in Washington, District of Columbia with additional offices in 21 countries across 5 continents (North America, South America, Asia, Australia and Europe).

Marvell Technology stock logo

Marvell Technology NASDAQ:MRVL

$59.28 -4.45 (-6.98%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$59.93 +0.65 (+1.10%)
As of 05/30/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Marvell Technology, Inc., together with its subsidiaries, provides data infrastructure semiconductor solutions, spanning the data center core to network edge. The company develops and scales complex System-on-a-Chip architectures, integrating analog, mixed-signal, and digital signal processing functionality. It offers a portfolio of Ethernet solutions, including controllers, network adapters, physical transceivers, and switches; single or multiple core processors; and custom application specific integrated circuits. The company also provides electro-optical products, including pulse amplitude modulations, coherent digital signal processors, laser drivers, trans-impedance amplifiers, silicon photonics, and data center interconnect solutions; fibre channel products comprising host bus adapters and controllers; storage controllers for hard disk drives and solid-state-drives; and host system interfaces, including serial attached SCSI, serial advanced technology attachment, peripheral component interconnect express, non-volatile memory express (NVMe), and NVMe over fabrics. It has operations in the United States, Argentina, China, India, Israel, Japan, Singapore, South Korea, Taiwan, and Vietnam. Marvell Technology, Inc. was incorporated in 1995 and is headquartered in Wilmington, Delaware.

Pfizer stock logo

Pfizer NYSE:PFE

$23.46 +0.01 (+0.04%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$23.52 +0.05 (+0.23%)
As of 05/30/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.